%A Fang Hongyan, Zhou Yunfeng %T Targeted therapy of advanced colorectal cancer %0 Journal Article %D 2016 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673-422X.2016.05.019 %P 391-394 %V 43 %N 5 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_9964.shtml} %8 2016-05-08 %X Targeted agents for advanced colorectal cancer mainly include inhibitors of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR). Studies show that bevacizumab and cetuximab can improve the prognosis of advanced colorectal cancer patients, but there is slight difference in the choice of chemotherapy regimens when combined with them. Bevacizumab and cetuximab can improve the overall survival of Kras wildtype colorectal cancer patients similarly. The emergence of new targeted drugs such as aflibercept, regorafenib provides more choices for the targeted therapy of advanced colorectal cancer patients.